McKesson Shares Surge as 11% Revenue Jump Triggers Outlook Hike

McKesson shares rallied following a third-quarter performance that outpaced Wall Street estimates, fueled by double-digit revenue growth and a strengthened full-year earnings forecast. The Irving, Texas-based pharmaceutical distributor reported a significant jump in profitability, driven by robust prescription volumes and an expansion in its specialty medicine portfolio.

February 5, 2026, 08:57 PM 0 0

The company reported a net income of $1.19 billion, or $9.59 per share, marking a substantial increase from the $879 million recorded during the same period last year. Adjusted earnings reached $9.34 per share, successfully clearing the $9.17 per share consensus estimate compiled by FactSet.

Total revenue climbed 11% to reach $106.16 billion, edging out analyst expectations of $105.8 billion. According to the company statement, this top-line momentum was primarily sustained by higher demand for prescription drugs and a strategic boost in the distribution of oncology and multispecialty products.

Upward Revision of Annual Guidance

Bolstered by the quarterly beat, McKesson raised its adjusted full-year earnings guidance to a range of $38.80 to $39.20 per share. The new forecast represents an increase from the previous projection of $38.35 to $38.85, placing the company’s outlook slightly ahead of the $38.90 per share anticipated by market analysts.

When reusing this material a link to Money Talk is required.